Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma

European Journal of Gynaecological Oncology

Volumn 29, Issue 5, 2008, Pages 459-461

  dos Santos, L G ^a   Lopes Costa, P V ^a   dos Santos, A R ^a   Facina, G ^b   da Silva, Benito Borges ^a,c  

^a FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Apoptosis; Bcl 2; Breast; Cancer; Estrogen receptor

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE; POSTMENOPAUSE; STAINING; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENES, BCL-2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; ONCOGENES; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN;

EID: 54949141734     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Simpson P.T., Reis-Filho J.S., Gale T., Lakhani S.R.: "Molecular evolution of breast cancer". J. Pathol., 2005, 205, 248.
2. Allred D.C., Harvey J.M., Berardo M., Clark G.M.: "Prognostic and predictive factors in breast cancer by immunohistochemical analysis". Mod. Pathod., 1998, 11, 155.
3. Teixeira C., Reed J.C., Pratt M.A.: "Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells". Cancer Res., 1995, 55, 3902.
4. Putti T.C., El-Rehim D.M., Rakha E.A., Paish C.E., Lee A.H., Pinder S.E. et al.: "Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis". Mod. Pathol., 2005, 18, 26.
5. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M. et al.: "Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999". Arch. Pathol. Lab. Med., 2000, 124, 966.
6. Krajewski S., Thor A.D., Edgerton S.M., Moore D.H. 2nd, Krajewska M., Reed J.C.: "Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers". Clin. Cancer Res., 1997, 3, 199.
7. Dowsett M., Archer C., Assersohn L., Gregory R.K., Ellis P.A., Salter J. et al.: "Clinical studies of apoptosis and proliferation in breast cancer". Endocr. Relat. Cancer, 1999, 6, 25.
8. Tan P.H., Bay B.H., Yip G., Selvarajan S, Tan P., Wu J. et al.: "Immunohistochemical detection of Ki-67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death". Mod. Pathol., 2005, 18, 374.
9. Johnston S.R., MacLennan K.A., Sacks N.P., Salter J., Smith I.E., Dowsett M.: "Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen". Eur. J. Cancer, 1994, 30A, 1663.
10. Lee H.D., Koo J.Y., Jung W.H.: "Correlations of Bcl-2 expression with clinicopathological features in breast cancer". Yonsei Med. J., 1997, 38, 206.
11. van Slooten H.J., Clahsen P.C., van Dierendonck J.H., DuvaL C., Pallud C., Mandard A.M. et al.: "Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy". Br. J. Cancer, 1996, 74, 78.
12. Jalava P., Kuopio T., Huovinen R., Laine J., Collan Y.: "Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints". Anti-cancer Res., 2005, 25, 2535.
13. Elston C.W., Ellis I.O., Goulding H., Pinder S.E.: "Role of pathology in the prognosis and management of breast cancer". In: Elston C.W. & Ellis I.O. (eds.): "The Breast". Edinburgh, Scotland, Churchill Livingstone 1998, 385.
14. Hlupic L., Jakic-Razumovic J., Bozikov J., Coric M., Belev B., Vrbanec D.: "Prognostic value of different factors in breast carcinoma". Tumori, 2004, 90, 112.
15. Gerdes J., Li L., Schlueter C., Durchrow M., Wohlenberg C., Gerlach C. et al.: "Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67". Am. J. Pathol., 1991, 138, 867.
16. Bozzetti C., Nizzoli R., Naldi N., Guazzi A., Camisa R., Bella M.A. et al.: "Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors". Cancer, 1999, 87, 224.
17. Bilalovic N., Vranic S., Hasanagic S., Basic H., Tatarevic A., Beslija S. et al.: "The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer". Bosn. J. Basic Med. Sci., 2004, 4, 5.
18. Hellemans P, van Dam P.A., Weyler J., van Oosterom A.T., Buytaert P., Van Marck E.: "Prognostic value of bcl-2 expression in invasive breast cancer". Br. J. Cancer, 1995, 72, 354.
19. Lee K.H., Im S.A., Oh D.Y., Lee S.H., Chie E.K., Han W. et al.: "Prognostic significance of bcl-2 expression in Stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy". BMC Cancer, 2007, 12, 7.
20. da Silva B.B., Lopes I.M., Gebrim L.H.: "Effects of raloxifene on normal breast tissue from premenopausal women". Breast Cancer Res. Treat., 2006, 95, 99.